Tag Archives: PE

China PE Firm Invests Up to $40M Per Company In Medtech, Diagnostics, and Digital Health

19 Jul

A private equity firm headquartered in China with additional offices throughout China and Hong Kong provides venture capital and growth capital to growth-stage companies across various industries, including life sciences, Internet, consumables, software, and high technology sectors (i.e. drones). The firm is interested in all types of life science companies except drug development. The allocation size will vary, but the firm has the capability to allocate up to $40 million per company, depending on the opportunity. The investment is typically in form of equity, but convertible loan will be considered as well. The firm has an emphasis on technologies and products, and it is currently seeking new investment opportunities globally. Companies with a China angle will be a big plus.

The firm is currently seeking to invest in medical device, diagnostics, biotech R&D services and healthcare IT sectors. The firm is very opportunistic in terms of subsectors and indications. Currently the firm will not invest in companies targeting drug development. The firm will consider companies at all stages of development, from pre-clinical stage all through to commercial stage; however, the firm prefers companies in the business proven stage, where the product is on the market and may already have customer feedback.

The firm primarily invests in growth-stage private companies. The firm does not have specific requirements for companies’ management team or revenues. The firm will take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Singapore-Based PE Firm Invests Up to $20M in All Areas of Life Sciences with Potential for Global Growth, Open to Any Stage of Development

12 Jul

A private equity and corporate finance advisory firm is headquartered in Singapore with a global presence. The firm makes global investments into life science and healthcare companies as well as services related to healthcare. The firm acts as a lead investor and utilizes their network to seek out other co-investors. Typical deal size is $0.5m to $20m. The firm will occasionally seek distribution rights for international investments.

The firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, healthcare services, biotech, R&D services and suppliers and engineering companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has no flexible investment criteria but the East West Axis is very important as the firm is not interested in companies that are restricted to one country. The firm looks for companies with a multinational, global component.

The firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have supported scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Hong Kong PE Firm Seeks to Invest Up to $10 M in Clinically Validated Medical Device and Diagnostics Products with China Angle

12 Jul

A PE firm that is headquartered in Hong Kong with additional offices throughout China currently manages over US$4 billion in assets and invests across several industry sectors including healthcare. The firm is interested in pre-growth and growth stage companies. Typical investment size ranges from US$5-10 million in Series A rounds. The firm seeks to lead but is open to syndicating with co-investors. The firm is now looking for opportunities in China, the US, and Canada.

Within healthcare, the firm focuses on medical devices and diagnostic technologies that have a China angle. The firm prefers products that have achieved clinical validation with proven advantages. The firm is also interested in clinical-stage biopharmaceutical opportunities as well as health information technology. The firm is opportunistic in terms of indication areas but is less interested in orphan diseases.

The firm is looking for experienced management teams with track record of success. The firm typically requests board representation in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: